Amicus Therapeutics Inc. (FOLD)
NASDAQ: FOLD
· Real-Time Price · USD
5.61
-0.05 (-0.88%)
At close: Jun 26, 2025, 1:58 PM
-0.88% (1D)
| Bid | 5.6 |
| Market Cap | 1.73B |
| Revenue (ttm) | 543.14M |
| Net Income (ttm) | -29.37M |
| EPS (ttm) | -0.09 |
| PE Ratio (ttm) | -62.3 |
| Forward PE | 21.96 |
| Analyst | Buy |
| Ask | 5.61 |
| Volume | 1,423,820 |
| Avg. Volume (20D) | 5,713,101.5 |
| Open | 5.72 |
| Previous Close | 5.66 |
| Day's Range | 5.55 - 5.78 |
| 52-Week Range | 5.51 - 12.65 |
| Beta | 0.53 |
About FOLD
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol FOLD
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for FOLD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Amicus Therapeutics Inc. is scheduled to release its earnings on Aug 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-13.02%
Amicus Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
8 months ago
+14%
Amicus Therapeutics shares are trading higher after the company announced it entered into a license agreement with Teva and resolved its Galafold patent litigation.
1 week ago · seekingalpha.com
Amicus Therapeutics: Opportunity Awaits In This Beaten Down PharmaAmicus Therapeutics is a commercial-stage biotech with a focused pipeline in Fabry, Pompe, and rare kidney diseases. Galafold, its lead therapy, is the only approved oral treatment for Fabry disease a...
1 month ago · seekingalpha.com
Amicus Therapeutics, Inc. (FOLD) Q1 2025 Earnings Call TranscriptAmicus Therapeutics, Inc. (NASDAQ:FOLD ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Andrew Faughnan - Vice President of Investor Relations Bradley Campbell - Presiden...
